Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol.Actinogen Medical's lead compound, Xanamem®, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive decline in Alzheimer's disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.Actinogen's clinical programme to date has demonstrated the safety and tolerability of Xanamem once daily in more than 200 healthy elderly volunteers and patients with Alzheimer's disease. A statistically significant improvement was observed on computerised cognition testing. These results, along with other data recently generated, confirm 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment.The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021. The XanaMIA study is planned to be conducted in two parts and is designed to study improvements in cognitive ability in older volunteers, and in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease. The XanaFX study studying male patients aged 12 to 18 will assess Xanamem's effects on cognition, anxiety, sleep and behavioural problems.

Website: actinogen.com.au

Employees: 10 - 19

HQ: N/A

Location: Sydney, NSW, AU

Revenue: 1 - 2.5 Million

Are you looking for contact information for Actinogen Medical? You're in luck! At ConnectPlex.ai, we provide comprehensive company data for millions of businesses worldwide, including Actinogen Medical. Our AI-powered algorithms ensure that our information is accurate and up-to-date, so you can trust that you're getting the most reliable contact details. Whether you're looking to collaborate, network, or do business with Actinogen Medical, ConnectPlex is the perfect platform to connect with the right people. Our database includes contact information for key decision-makers, executives, and employees at Actinogen Medical, making it easy for you to get in touch with the right person. With our user-friendly interface and advanced search filters, you can quickly and easily find the contact information you need. So why wait? Sign up for ConnectPlex.ai today and start connecting with the people that matter most to your business.

Actinogen Medical is a biotechnology company based in Sydney, Australia, that is dedicated to developing innovative therapies for neurological diseases associated with dysregulated brain cortisol. The company's lead compound, Xanamem, has shown promise in reducing production of intracellular cortisol through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in areas of the brain associated with cognitive decline in Alzheimer's disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. Actinogen's clinical program has demonstrated the safety and tolerability of Xanamem in more than 200 healthy elderly volunteers and patients with Alzheimer's disease, with a statistically significant improvement observed on computerized cognition testing. The company plans to initiate Phase II studies of Xanamem in various disease areas in 2021, including the XanaMIA study in older volunteers and patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease, and the XanaFX study in male patients aged 12 to 18 to assess Xanamem's effects on cognition, anxiety, sleep, and behavioural problems. With a strong management team led by Chief Executive Officer Steven Gourlay and Chief Financial Officer Jeff Carter, Actinogen Medical is well-positioned to make a significant impact in the field of neurological diseases. The company's innovative approach and commitment to developing novel therapies have the potential to improve the lives of millions of people worldwide.

Actinogen Medical is a company that is working on new treatments for diseases that affect the brain, like Alzheimer's disease. They have a drug called Xanamem that can reduce the amount of a stress hormone called cortisol in the brain. This hormone can cause problems with memory, thinking, and behavior when it's produced in excess. Xanamem works by blocking an enzyme in the brain that helps make cortisol. The company has tested Xanamem on healthy older people and people with Alzheimer's disease, and the results show that it's safe and can improve cognitive function. They plan to do more studies in 2021 to see if it can help people with other diseases that affect the brain. One study will test Xanamem in older people to see if it can improve their memory and thinking skills. Another study will test it in boys aged 12 to 18 to see if it can help with anxiety, sleep problems, and behavioral issues. Overall, Actinogen Medical is working on a promising new treatment that could help people with a range of brain-related diseases.